Market Cap 32.08B
Revenue (ttm) 1.70B
Net Income (ttm) -190.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -11.22%
Debt to Equity Ratio 0.06
Volume 1,363,000
Avg Vol 1,404,526
Day's Range N/A - N/A
Shares Out 138.32M
Stochastic %K 30%
Beta 1.63
Analysts Strong Sell
Price Target $237.16

Company Profile

Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples und...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 650 980 9190
Address:
13011 McCallen Pass, Building A Suite 100, Austin, United States
kevin_davis07f
kevin_davis07f Dec. 12 at 5:47 PM
$NTRA Mainz Biomed is literally pennies under VWAP ~1.027 at ~$1.01–$1.02 while the last box is 1.04–1.14, I’m holding for the reclaim because catalysts like UK MHRA access + ~4,000,000 annual screening invites is how microcaps wake up fast
0 · Reply
WAJeff
WAJeff Dec. 12 at 12:10 AM
$TEVA 54% rise the last three months. Tell me Druck is not a legend $NTRA $INSM $TSM
2 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:01 PM
Actionable Trade Alert for $NTRA: Market Context: $NTRA is currently trading at $230.37, showing a stable position within its recent range. The RSI at 55.19 indicates a neutral to slightly bullish momentum, suggesting potential for upward movement. Directional Bias: The price is above the 30-day moving average (MA30) of 219.72 and the 50-day moving average (MA50) of 203.74, indicating a bullish trend. The recent 60-day high of 246.9 provides a clear resistance level, while the low of 157.43 establishes a solid support base. Trade Plan: - Suggested Entry: $230.37 - Stop Loss: $223.00 (approximately 3.3% below entry) - Take Profit Targets: 1. $240.00 (4.2% gain) 2. $250.00 (8.5% gain) 3. $270.00 (17.2% gain) This plan offers a risk-reward ratio that supports a potential 17% ROI or more on the third target. Monitor closely for price action around the targets. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
olivia_foster19
olivia_foster19 Dec. 11 at 7:39 PM
$NTRA Mainz Biomed looks “boring” only if you don’t trade tape, every time bids stack at 1.04–1.05 sellers dry up and price pops right back toward 1.08–1.10 💪
0 · Reply
Bogwood
Bogwood Dec. 11 at 6:03 PM
$IMDX Even with all of this year's press releases and events, most still don't see what's going to happen to transplant diagnostics next year and see the situation as not yet "derisked". Do not be deterred by recent price movement fellow holders! The path to $100M top line will light like a tinder box. 80% of the top transplant centers already perform HLA in-house. $NTRA and $CDNA can kiss their biz model goodbye 💋
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 3:04 AM
Actionable Trade Alert for $NTRA: Market Context: $NTRA is currently trading at $235.53, showing strong momentum but also indicating overbought conditions with an RSI of 70.56. This suggests a potential pullback may occur. However, the stock is above its 30-day moving average (MA30) of 217.02 and 50-day moving average (MA50) of 200.92, indicating bullish sentiment in the medium term. Directional Bias: Given the RSI and the proximity to the 60-day high of 246.9, we expect a short-term pullback followed by a potential breakout. The price is well above the 60-day low of 157.43, reinforcing bullish sentiment. Trade Plan: - Suggested Entry: $235.53 - Stop Loss: $228.07 (below recent support) - Take Profit Targets: 1. $240.00 (2% gain) 2. $245.00 (4% gain) 3. $276.00 (17% gain) This plan allows for a solid risk-reward ratio with potential for significant ROI. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 10:52 PM
Actionable Trade Alert for $NTRA: Market Context: $NTRA is currently trading at $241.64, near its 60D high of $246.9, indicating strong bullish momentum. The RSI of 82.53 suggests that the stock is overbought, which could lead to a potential pullback. However, the upward trend is supported by the MA30 at $215.66 and MA50 at $199.52, indicating a solid bullish trend in the short to medium term. Directional Bias: Bullish, but caution is warranted due to the high RSI reading. Trade Plan: - Suggested Entry: $241.64 - Stop Loss: $230.00 (approximately 4.8% below entry) - Take Profit Targets: 1. $250.00 (3.4% gain) 2. $260.00 (7.6% gain) 3. $283.00 (17.1% gain) With a potential 17% ROI on the third target, this trade offers a favorable risk-reward ratio. Monitor the RSI for signs of reversal and adjust stop loss accordingly. https://privateprofiteers.com
0 · Reply
WAJeff
WAJeff Dec. 8 at 7:47 PM
$NTRA 247.10 ath before the fade
0 · Reply
JarvisFlow
JarvisFlow Dec. 8 at 6:01 PM
Canaccord Genuity has updated their rating for Natera ( $NTRA ) to Buy with a price target of 250.
0 · Reply
JarvisFlow
JarvisFlow Dec. 8 at 2:37 PM
BTIG has updated their rating for Natera ( $NTRA ) to Buy with a price target of 260.
0 · Reply
Latest News on NTRA
Natera Acquires Foresight Diagnostics

Dec 5, 2025, 7:00 AM EST - 8 days ago

Natera Acquires Foresight Diagnostics


Natera Integrates with Flatiron Health's OncoEMR® Platform

Nov 12, 2025, 8:00 AM EST - 4 weeks ago

Natera Integrates with Flatiron Health's OncoEMR® Platform


Natera, Inc. (NTRA) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 8:36 PM EST - 5 weeks ago

Natera, Inc. (NTRA) Q3 2025 Earnings Call Transcript


Natera Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:05 PM EST - 5 weeks ago

Natera Reports Third Quarter 2025 Financial Results


Natera to Report its Third Quarter Results on November 6, 2025

Oct 30, 2025, 7:00 AM EDT - 6 weeks ago

Natera to Report its Third Quarter Results on November 6, 2025


Natera Named to Fast Company's Next Big Things in Tech List

Oct 16, 2025, 8:00 AM EDT - 2 months ago

Natera Named to Fast Company's Next Big Things in Tech List


Can Natera Stock Reach $500?

Sep 15, 2025, 10:10 AM EDT - 3 months ago

Can Natera Stock Reach $500?


Natera Provides Update on Patent Litigation with NeoGenomics

Aug 29, 2025, 8:18 AM EDT - 3 months ago

Natera Provides Update on Patent Litigation with NeoGenomics


Natera, Inc. (NTRA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 10:43 PM EDT - 4 months ago

Natera, Inc. (NTRA) Q2 2025 Earnings Call Transcript


Natera (NTRA) Q2 Revenue Jumps 32%

Aug 7, 2025, 5:54 PM EDT - 4 months ago

Natera (NTRA) Q2 Revenue Jumps 32%


Natera Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 4 months ago

Natera Reports Second Quarter 2025 Financial Results


Natera to Report Its Second Quarter Results on August 7, 2025

Jul 31, 2025, 7:00 AM EDT - 4 months ago

Natera to Report Its Second Quarter Results on August 7, 2025


Natera Announces Medicare Coverage for Signatera™ Genome

Jun 4, 2025, 7:00 AM EDT - 6 months ago

Natera Announces Medicare Coverage for Signatera™ Genome


kevin_davis07f
kevin_davis07f Dec. 12 at 5:47 PM
$NTRA Mainz Biomed is literally pennies under VWAP ~1.027 at ~$1.01–$1.02 while the last box is 1.04–1.14, I’m holding for the reclaim because catalysts like UK MHRA access + ~4,000,000 annual screening invites is how microcaps wake up fast
0 · Reply
WAJeff
WAJeff Dec. 12 at 12:10 AM
$TEVA 54% rise the last three months. Tell me Druck is not a legend $NTRA $INSM $TSM
2 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:01 PM
Actionable Trade Alert for $NTRA: Market Context: $NTRA is currently trading at $230.37, showing a stable position within its recent range. The RSI at 55.19 indicates a neutral to slightly bullish momentum, suggesting potential for upward movement. Directional Bias: The price is above the 30-day moving average (MA30) of 219.72 and the 50-day moving average (MA50) of 203.74, indicating a bullish trend. The recent 60-day high of 246.9 provides a clear resistance level, while the low of 157.43 establishes a solid support base. Trade Plan: - Suggested Entry: $230.37 - Stop Loss: $223.00 (approximately 3.3% below entry) - Take Profit Targets: 1. $240.00 (4.2% gain) 2. $250.00 (8.5% gain) 3. $270.00 (17.2% gain) This plan offers a risk-reward ratio that supports a potential 17% ROI or more on the third target. Monitor closely for price action around the targets. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
olivia_foster19
olivia_foster19 Dec. 11 at 7:39 PM
$NTRA Mainz Biomed looks “boring” only if you don’t trade tape, every time bids stack at 1.04–1.05 sellers dry up and price pops right back toward 1.08–1.10 💪
0 · Reply
Bogwood
Bogwood Dec. 11 at 6:03 PM
$IMDX Even with all of this year's press releases and events, most still don't see what's going to happen to transplant diagnostics next year and see the situation as not yet "derisked". Do not be deterred by recent price movement fellow holders! The path to $100M top line will light like a tinder box. 80% of the top transplant centers already perform HLA in-house. $NTRA and $CDNA can kiss their biz model goodbye 💋
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 3:04 AM
Actionable Trade Alert for $NTRA: Market Context: $NTRA is currently trading at $235.53, showing strong momentum but also indicating overbought conditions with an RSI of 70.56. This suggests a potential pullback may occur. However, the stock is above its 30-day moving average (MA30) of 217.02 and 50-day moving average (MA50) of 200.92, indicating bullish sentiment in the medium term. Directional Bias: Given the RSI and the proximity to the 60-day high of 246.9, we expect a short-term pullback followed by a potential breakout. The price is well above the 60-day low of 157.43, reinforcing bullish sentiment. Trade Plan: - Suggested Entry: $235.53 - Stop Loss: $228.07 (below recent support) - Take Profit Targets: 1. $240.00 (2% gain) 2. $245.00 (4% gain) 3. $276.00 (17% gain) This plan allows for a solid risk-reward ratio with potential for significant ROI. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 10:52 PM
Actionable Trade Alert for $NTRA: Market Context: $NTRA is currently trading at $241.64, near its 60D high of $246.9, indicating strong bullish momentum. The RSI of 82.53 suggests that the stock is overbought, which could lead to a potential pullback. However, the upward trend is supported by the MA30 at $215.66 and MA50 at $199.52, indicating a solid bullish trend in the short to medium term. Directional Bias: Bullish, but caution is warranted due to the high RSI reading. Trade Plan: - Suggested Entry: $241.64 - Stop Loss: $230.00 (approximately 4.8% below entry) - Take Profit Targets: 1. $250.00 (3.4% gain) 2. $260.00 (7.6% gain) 3. $283.00 (17.1% gain) With a potential 17% ROI on the third target, this trade offers a favorable risk-reward ratio. Monitor the RSI for signs of reversal and adjust stop loss accordingly. https://privateprofiteers.com
0 · Reply
WAJeff
WAJeff Dec. 8 at 7:47 PM
$NTRA 247.10 ath before the fade
0 · Reply
JarvisFlow
JarvisFlow Dec. 8 at 6:01 PM
Canaccord Genuity has updated their rating for Natera ( $NTRA ) to Buy with a price target of 250.
0 · Reply
JarvisFlow
JarvisFlow Dec. 8 at 2:37 PM
BTIG has updated their rating for Natera ( $NTRA ) to Buy with a price target of 260.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 1:53 AM
Actionable Trade Alert for $NTRA: Market Context: $NTRA closed at $242.06, approaching the 60D high of $243.73. The RSI is at 87.84, indicating an overbought condition, suggesting potential for a pullback. The MA30 and MA50 are significantly lower at 212.37 and 196.33, respectively, indicating a strong upward trend but also highlighting potential volatility. Directional Bias: The current price is near the high of the 60-day range, which could lead to a reversal. However, the strong upward momentum suggests a cautious bullish stance. Trade Plan: - Suggested Entry: $242.06 - Stop Loss: $235.26 (below recent support, approximately 3% downside) - Take Profit Targets: 1. Target 1: $250.00 (3.3% gain) 2. Target 2: $260.00 (7.4% gain) 3. Target 3: $284.00 (17.3% gain) This plan aims for a minimum of 17% ROI on the third target while managing risk with a reasonable stop loss. Monitor RSI for signs of reversal before entering. https://privateprofiteers.com
0 · Reply
invisiblesurfer
invisiblesurfer Dec. 5 at 1:50 PM
$NTRA acquired Foresight DX, enters lymphoma and potentially blood tumours space. https://www.businesswire.com/news/home/20251205184980/en/Natera-Acquires-Foresight-Diagnostics?utm_campaign=shareaholic&utm_medium=copy_link&utm_source=bookmark
0 · Reply
Estimize
Estimize Dec. 4 at 9:00 PM
Wall St is expecting -0.50 EPS for $NTRA Q4 [Reporting 03/04 AMC] http://www.estimize.com/intro/ntra?chart=historical&metric_name=eps&utm_c
0 · Reply
oaksapollo
oaksapollo Dec. 4 at 4:56 PM
$GH and $NTRA have a combined cap of nearly $50B now, while shares of poor neglected $LUCD can be purchased for $1 ($140M cap). Pretty crazy given they are the only player in the $30B esophageal cancer screening space. There is no questioning the TAM - pricing has already been set by CMS at $1932 and there are good data defining the screening population at 30M people (per ACG guidance). And yes, I know, their history is not glamorous. IPO’d at $14 and traded to pennies, but after a long journey they are finally on the cusp of broad coverage with all of the GI community rooting for them. Test volume and revenue will scale quickly.
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 3 at 10:41 AM
$NTRA $NTSK $NU $NUAI $NUE Cycle Trading Signal plugged into AI 🔥 lists 🔥 Undeniable Accuracy 🔥
0 · Reply
erevnon
erevnon Dec. 2 at 6:30 PM
Morgan Stanley maintains Natera $NTRA at Overweight and raises the price target from $220 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
JarvisFlow
JarvisFlow Dec. 2 at 5:49 PM
Morgan Stanley updates rating for Natera ( $NTRA ) to Overweight, target set at 220 → 265.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 2 at 2:25 PM
$NTRA Current Stock Price: $234.28 Contracts to trade: $230 NTRA Dec 19 2025 Call Entry: $10.84 Exit: $18.75 ROI: 73% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 1 at 11:42 AM
$NTRA Share Price: $238.72 Contract Selected: May 15, 2026 $240 Calls Buy Zone: $23.26 – $28.73 Target Zone: $42.20 – $51.58 Potential Upside: 71% ROI Time to Expiration: 164 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
glynch2001
glynch2001 Dec. 1 at 12:42 AM
$NTRA $GRAL $PSNL $TWST starting to watch. Am I missing any others?
1 · Reply
PolycarpFX
PolycarpFX Nov. 29 at 3:57 PM
$NTRA Natera Inc, a top holding of legendary investor Stanley Druckenmillers fund.
0 · Reply
MaverikIT
MaverikIT Nov. 26 at 3:44 PM
$NTRA +2.72 - been lovely
0 · Reply